Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis

Neuroepidemiology - Tập 36 Số 2 - Trang 123-133 - 2011
James J. Sejvar1, Andrew L. Baughman1, Matt P. Wise1, Oliver Morgan
1Division of High-Consequence Pathogens and Pathology and Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga., USA

Tóm tắt

Population incidence of Guillain-Barré syndrome (GBS) is required to assess changes in GBS epidemiology, but published estimates of GBS incidence vary greatly depending on case ascertainment, definitions, and sample size. We performed a meta-analysis of articles on GBS incidence by searching Medline (1966–2009), Embase (1988–2009), Cinahl (1981–2009) and CABI (1973–2009) as well as article bibliographies. We included studies from North America and Europe with at least 20 cases, and used population-based data, subject matter experts to confirm GBS diagnosis, and an accepted GBS case definition. With these data, we fitted a random-effects negative binomial regression model to estimate age-specific GBS incidence. Of 1,683 nonduplicate citations, 16 met the inclusion criteria, which produced 1,643 cases and 152.7 million person-years of follow-up. GBS incidence increased by 20% for every 10-year increase in age; the risk of GBS was higher for males than females. The regression equation for calculating the average GBS rate per 100,000 person-years as a function of age in years was exp[–12.0771 + 0.01813(age in years)] × 100,000. Our findings provide a robust estimate of background GBS incidence in Western countries. Our regression model may be used in comparable populations to estimate the background age-specific rate of GBS incidence for future studies.

Từ khóa


Tài liệu tham khảo

10.1016%2FS0140-6736%2805%2967665-9

10.1016%2FS0165-5728%2899%2900195-2

10.1002%2Fana.410440115

10.1056%2FNEJM199511233332102

10.1002%2Fana.410120202

10.1016%2FS0140-6736%2809%2961877-8

10.1159%2F000184748

10.1093%2Fbrain%2F118.3.577

10.1002%2Fana.410030628

10.1002%2Fana.410270707

10.1016%2Fj.vaccine.2010.06.003

10.1111%2Fj.1467-985X.2008.00552.x

10.1136%2Fjnnp.65.2.218

10.1007%2FBF01999898

10.1111%2Fj.1600-0404.2004.00272.x

10.1046%2Fj.1468-1331.2000.00128.x

10.1159%2F000050769

10.1007%2Fs10072-004-0231-6

10.1016%2FS0022-510X%2803%2900215-6

10.1136%2Fjnnp.64.1.74

10.1111%2Fj.1600-0404.1994.tb01682.x

10.1212%2FWNL.54.3.620

10.1093%2Fqjmed%2F77.3.1297

10.1007%2Fs100720200036

10.1002%2Fana.410300418

10.1177%2F0883073810370481

10.1111%2Fj.1651-2227.2010.01860.x

10.1186%2F2042-6410-2-1

10.3109%2F00207454.2010.539307